Literature DB >> 25628418

Aldosterone Contributes to Sympathoexcitation in Renovascular Hypertension.

Gisele S Lincevicius1, Caroline G Shimoura1, Erika E Nishi1, Juliana C Perry2, Dulce E Casarini3, Guiomar N Gomes1, Cássia T Bergamaschi1, Ruy R Campos4.   

Abstract

BACKGROUND: Although angiotensin II (Ang II) is essential to the development of renovascular hypertension, aldosterone plays a role as well. Recent studies have demonstrated a cross-talk between Ang II type 1 and mineralocorticoid receptors in the brain and kidneys. However, the role of aldosterone in the autonomic and renal dysfunction of renovascular hypertension is not well understood. AIM: The current study evaluated whether aldosterone contributes to cardiovascular and renal dysfunction in the 2 kidney-1 clip (2K1C) model.
METHODS: Mean arterial pressure (MAP) and baroreceptor reflex for control of the heart rate were evaluated in 2K1C treated or not treated with spironolactone (200mg/kg/day, 7 days). Tonic and reflex control of renal sympathetic nerve activity (rSNA) were assessed in urethane-anaesthetized rats. Plasma renin activity (PRA), kidney renin protein expression, renal injury, and central AT1 receptor protein expression were assessed.
RESULTS: Spiro reduced MAP (198±4 vs. 170±9mm Hg; P < 0.05), normalized rSNA (147±9 vs. 96±10 pps; P < 0.05), and increased renal baroreceptor reflex sensitivity in the 2K1C rats. Spiro reduced α-smooth muscle actin expression in the nonclipped kidney in the 2K1C group (5±0.6 vs. 1.1±0.2%; P < 0.05). There was no change in PRA; however, a decrease in renin protein expression in the nonclipped kidney was found in the 2K1C treated group (217±30 vs. 160±19%; P < 0.05). Spiro treatment decreased AT1 receptor in the central nervous system (CNS) only in 2K1C rats (138±10 vs. 84±12%; P < 0.05).
CONCLUSION: Aldosterone contributes to autonomic dysfunction and intrarenal injury in 2K1C, these effects are mediated by the CNS. © American Journal of Hypertension, Ltd 2015. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  baroreflex dysfunction; blood pressure; hypertension; renal injury; renin–angiotensin–aldosterone; renovascular hypertension; sympathoexcitation.

Mesh:

Substances:

Year:  2015        PMID: 25628418     DOI: 10.1093/ajh/hpu300

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  6 in total

Review 1.  The renin-angiotensin system in cardiovascular autonomic control: recent developments and clinical implications.

Authors:  Amanda J Miller; Amy C Arnold
Journal:  Clin Auton Res       Date:  2018-11-09       Impact factor: 4.435

2.  Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure.

Authors:  Guangqiu Feng; Yu Yang; Juan Chen; Zhiyong Wu; Yin Zheng; Wei Li; Wenxin Dai; Pin Guan; Chunrong Zhong
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

3.  Carotid sinus denervation ameliorates renovascular hypertension in adult Wistar rats.

Authors:  Wioletta Pijacka; Fiona D McBryde; Paul J Marvar; Gisele S Lincevicius; Ana P L Abdala; Lavinia Woodward; Dan Li; David J Paterson; Julian F R Paton
Journal:  J Physiol       Date:  2016-09-23       Impact factor: 5.182

4.  Variable role of carotid bodies in cardiovascular responses to exercise, hypoxia and hypercapnia in spontaneously hypertensive rats.

Authors:  Wioletta Pijacka; Pedro L Katayama; Helio C Salgado; Gisele S Lincevicius; Ruy R Campos; Fiona D McBryde; Julian F R Paton
Journal:  J Physiol       Date:  2018-02-12       Impact factor: 5.182

5.  Effects of voluntary exercise on blood pressure, angiotensin II, aldosterone, and renal function in two-kidney, one-clip hypertensive rats.

Authors:  Brian M Waldman; Robert A Augustyniak; Haiping Chen; Noreen F Rossi
Journal:  Integr Blood Press Control       Date:  2017-11-29

6.  Effects of spironolactone on extrasystoles and heart rate variability in haemodialysis patients: a randomised crossover trial.

Authors:  Michael Eklund; Olof Hellberg; Hans Furuland; Yang Cao; Erik Nilsson
Journal:  Ups J Med Sci       Date:  2021-01-25       Impact factor: 2.384

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.